New drug shows promise in slowing brain metastases from lung cancer
NCT ID NCT03653546
Summary
This study tested if a new drug, AZD3759, could control advanced lung cancer that had spread to the brain better than standard drugs. It involved nearly 500 adults with a specific genetic mutation (EGFR+) who had not yet received treatment for their advanced cancer. The main goal was to see if the new drug could keep the cancer from getting worse for a longer period, both in the brain and the rest of the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China site
Hefei, Anhui, 230001, China
-
China site
Chongqing, China, 400037, China
-
China site
Fuzhou, Fujian, 350014, China
-
China site
Xiamen, Fujian, 361003, China
-
China site
Guangzhou, Guangdong, 510080, China
-
China site
Guangzhou, Guangdong, 510180, China
-
China site
Haerbin, Heilongjiang, 150081, China
-
China site
Zhengzhou, Henan, 450008, China
-
China site
Zhengzhou, Henan, 450052, China
-
China site
Wuhan, Hubei, 430022, China
-
China site
Wuhan, Hubei, 430030, China
-
China site
Wuhan, Hubei, 430079, China
-
China site
Yichang, Hubei, 443003, China
-
China site
Changsha, Hunan, 410013, China
-
China site
Nanjing, Jiangsu, 210002, China
-
China site
Nanjing, Jiangsu, 210009, China
-
China site
Suzhou, Jiangsu, 215004, China
-
China site
Wuxi, Jiangsu, 214062, China
-
China site
Xuzhou, Jiangsu, 221002, China
-
China site
Yangzhou, Jiangsu, 225001, China
-
China site
Changchun, Jilin, 130012, China
-
China site
Changchun, Jilin, 130021, China
-
China site
Xi'an, Shaanxi, 710061, China
-
China site
Linyi, Shandong, 276000, China
-
China site
Weifang, Shandong, 261000, China
-
China site
Yantai, Shandong, 264000, China
-
China site
Chengdu, Sichuan, 610041, China
-
China site
Kunming, Yunnan, 650118, China
-
China site
Hangzhou, Zhejiang, 310003, China
-
China site
Hangzhou, Zhejiang, 310022, China
-
China site
Hangzhou, Zhejiang, 311100, China
-
China site
Beijing, 100021, China
-
China site
Beijing, 100071, China
-
China site
Beijing, 100142, China
-
China site
Beijing, 100730, China
-
China site
Chongqing, 400030, China
-
China site
Chongqing, 400042, China
-
China site
Shanghai, 200030, China
-
China site
Shanghai, 200032, China
-
China site
Tianjin, 300052, China
-
China site 0123
Jinan, Shandong, 250117, China
-
Korea Site
Jungbuk, 28644, South Korea
-
Korea Site
Seoul, 03080, South Korea
-
Korea Site
Seoul, 06351, South Korea
-
Korea site
Daegu, 42415, South Korea
-
Korea site
Gyeonggi-do, 16247, South Korea
-
Korea site
Gyeongsang, 52727, South Korea
-
Korea site
Incheon, 21565, South Korea
-
Korea site
Seoul, 05368, South Korea
-
Korea site
Seoul, 06591, South Korea
-
Korea site
Seoul, 07061, South Korea
-
Korea site
Suwon, 16499, South Korea
-
Korea site
Ulsan, 44033, South Korea
-
Singapore site
Singapore, 308433, Singapore
-
Taiwan site
Taichung, 407, Taiwan
-
Taiwan site
Tainan, 704, Taiwan
-
Taiwan site
Taipei, 100, Taiwan
-
Taiwan site
Taoyuan District, 333, Taiwan
Conditions
Explore the condition pages connected to this study.